FUNDAMENTALS · Fundamentals · JP Healthcare

CE Holdings (4320) Fundamentals 2026 — P/E 18.5x, Revenue Analysis | SniperIQ

CE Holdings (4320) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥28.9B, trading at ¥1732.00 on the JPX. This SniperIQ fundamentals page covers CE Holdings's valuation (P/E 18.5x, P/B 3.5x), profitability (net margin 8.9%), revenue (¥15.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥28.9B
P/E (TTM)18.5x
Net Margin8.9%
Revenue (FY25)¥15.8B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is CE Holdings's market cap?

CE Holdings (4320) has a market capitalization of approximately ¥28.9B, trading at ¥1732.00 on the JPX. Market cap moves with the live share price.

What is CE Holdings's P/E ratio?

CE Holdings's trailing twelve-month P/E ratio is 18.5x, with a price-to-book (P/B) of 3.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is CE Holdings?

CE Holdings runs a net profit margin of 8.9%, a gross margin of 22.1%, and an operating margin of 9.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CE Holdings generate?

CE Holdings reported revenue of ¥15.8B for fiscal year 2025, with net income of ¥1.6B and earnings per share (EPS) of 98.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CE Holdings pay a dividend?

CE Holdings offers a trailing dividend yield of about 3.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is CE Holdings financially healthy?

CE Holdings carries a debt-to-equity ratio of 0.24x and a current ratio of 2.24x, with a market beta of 0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CE Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CE Holdings (4320) the key facts are: market cap ¥28.9B, P/E 18.5x, revenue ¥15.8B, 52-week range 675-1859. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track CE Holdings's full fundamentals live

Get CE Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Center Laboratories (4123) fundamentals · Shijiazhuang Yiling Pharmaceutical (002603) fundamentals · Tdspharm (464280) fundamentals · Panacea Biotec (PANACEABIO) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons